NasdaqGS - Delayed Quote • USD
Compare
At close: August 14 at 4:00 PM EDT
After hours: August 14 at 5:34 PM EDT
Line
Candle
Baseline
Mountain
Bar
Loading Chart for GRFS
9/21 12:03 PM
DELL
Date | |
Close | |
Open | |
High | |
Low | |
Volume |
- Previous Close
6.89 - Open
6.89 - Bid 6.90 x 300
- Ask 6.96 x 100
- Day's Range
6.76 - 6.93 - 52 Week Range
5.30 - 12.15 - Volume
477,954 - Avg. Volume
1,480,390 - Market Cap (intraday)
5.582B - Beta (5Y Monthly) 0.70
- PE Ratio (TTM)
26.58 - EPS (TTM)
0.26 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 3, 2021
- 1y Target Est
11.64
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
23,505
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Drug Manufacturers - General
Industry
More about Grifols, S.A.
Recent News: GRFS
View MoreAll SEC Filings
Corporate Changes & Voting Matters
Periodic Financial Reports
Proxy Statements
Tender Offer/Acquisition Reports
Offering Registrations
Performance Overview: GRFS
Trailing total returns as of 8/14/2024, which may include dividends or other distributions. Benchmark is IBEX 35...
YTD Return
GRFS
40.22%
IBEX 35...
6.44%
1-Year Return
GRFS
31.65%
IBEX 35...
13.98%
3-Year Return
GRFS
51.64%
IBEX 35...
19.48%
5-Year Return
GRFS
66.85%
IBEX 35...
23.67%
Compare To: GRFS
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
6.91
+0.29%
Mkt Cap 5.582B
Industry Drug Manufacturers—General
53.53
-0.09%
Mkt Cap 134.176B
Industry Drug Manufacturers—General
113.53
+0.89%
Mkt Cap 229.851B
Industry Drug Manufacturers—General
19.97
-1.58%
Mkt Cap 5.142B
Industry Drug Manufacturers—General
41.22
+0.10%
Mkt Cap 84.067B
Industry Drug Manufacturers—General
200.59
-1.70%
Mkt Cap 29.218B
Industry Drug Manufacturers—General
7.13
-0.42%
Mkt Cap 28.019B
Industry Drug Manufacturers—General
40.64
+0.57%
Mkt Cap 261.574B
Industry Drug Manufacturers—General
83.76
+0.47%
Mkt Cap 259.701B
Industry Drug Manufacturers—General
25.84
-0.58%
Mkt Cap EUR 25.381B
Industry Drug Manufacturers—General
324.00
+1.01%
Mkt Cap 263.074B
Industry Drug Manufacturers—General
Statistics: GRFS
View More
Valuation Measures
As of 8/13/2024
Market Cap
5.57B
Enterprise Value
14.75B
Trailing P/E
26.31
Forward P/E
12.38
PEG Ratio (5yr expected)
0.22
Price/Sales (ttm)
0.64
Price/Book (mrq)
0.77
Enterprise Value/Revenue
1.98
Enterprise Value/EBITDA
9.78
Financial Highlights
Profitability and Income Statement
Profit Margin
2.43%
Return on Assets (ttm)
2.47%
Return on Equity (ttm)
2.82%
Revenue (ttm)
6.81B
Net Income Avi to Common (ttm)
165.67M
Diluted EPS (ttm)
0.26
Balance Sheet and Cash Flow
Total Cash (mrq)
2.26B
Total Debt/Equity (mrq)
138.69%
Levered Free Cash Flow (ttm)
159.47M
Research Analysis: GRFS
View MoreCompany Insights: GRFS
Research Reports: GRFS
View MorePeople Also Watch
IRWD Ironwood Pharmaceuticals, Inc.
4.3400
-3.34%
HCM HUTCHMED (China) Limited
19.11
-5.91%
LIVN LivaNova PLC
45.57
+3.03%
FMS Fresenius Medical Care AG
18.78
+0.37%
GLPG Galapagos NV
24.20
-1.06%
ARGX argenx SE
522.36
-1.63%
ENTA Enanta Pharmaceuticals, Inc.
11.57
-8.25%
PCRX Pacira BioSciences, Inc.
12.47
+0.56%
RARE Ultragenyx Pharmaceutical Inc.
51.76
-0.08%
ZLAB Zai Lab Limited
16.25
0.00%
APLS Apellis Pharmaceuticals, Inc.
36.02
+0.84%
BGNE BeiGene, Ltd.
186.70
-0.27%
PTCT PTC Therapeutics, Inc.
31.77
-0.31%
GMAB Genmab A/S
26.80
+0.87%
DNLI Denali Therapeutics Inc.
22.48
-2.35%
SGRY Surgery Partners, Inc.
29.14
-2.87%